Mikhail Ivanov

Dr. Mikhail Ivanov

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2023 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
VCVasiliy Chernyshev
Vasiliy Chernyshev
AYAlexey Yashchenok
Alexey Yashchenok
MIMikhail Ivanov
Mikhail Ivanov
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Isolation, purification and analysis of extracellular vesicles (EVs) by using low cost, versatile, easy to use and compatible with different biofluids filtration-based technologies for industrial, medical and research applications.

Verified
Journal Article
Open access
PDF file
KGKirill Goryunov
Kirill Goryunov
MIMikhail Ivanov
Mikhail Ivanov
AKAndrey Kulikov
Andrey Kulikov
YSYulia Shevtsova
Yulia Shevtsova
ABArtem Burov
Artem Burov
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Neonatal disorders, particularly those resulting from prematurity, pose a major challenge in health care and have a significant impact on infant mortality and long-term child health. The limitations of current therapeutic strategies emphasize the need for innovative treatments. New cell-free technologies utilizing extracellular vesicles (EVs) offer a compelling opportunity for neonatal therapy by harnessing the inherent regenerative capabilities of EVs. These nanoscale particles, secreted by a variety of organisms including animals, bacteria, fungi and plants, contain a repertoire of bioactive molecules with therapeutic potential. This review aims to provide a comprehensive assessment of the therapeutic effects of EVs and mechanistic insights into EVs from stem cells, biological fluids and non-animal sources, with a focus on common neonatal conditions such as hypoxic–ischemic encephalopathy, respiratory distress syndrome, bronchopulmonary dysplasia and necrotizing enterocolitis. This review summarizes evidence for the therapeutic potential of EVs, analyzes evidence of their mechanisms of action and discusses the challenges associated with the implementation of EV-based therapies in neonatal clinical practice.

Verified
Journal Article
Open access
PDF file
AGArtem Gureev
Artem Gureev
VNVeronika Nesterova
Veronika Nesterova
PBPolina I. Babenkova
Polina I. Babenkova
MIMikhail Ivanov
Mikhail Ivanov
Egor PlotnikovEgor Plotnikov
Egor Plotnikov
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Traumatic brain injuries (TBIs) are a serious problem affecting individuals of all ages. Mitochondrial dysfunctions represent a significant form of secondary injury and may serve as a promising target for therapeutic intervention. Our research demonstrated that craniotomy, which precedes the experimental induction of trauma in mice, can cause considerable damage to mitochondrial DNA (mtDNA), disrupt the regulatory expression of angiogenesis, and increase inflammation. However, the reduction in the mtDNA copy number and glial activation occur only after a direct impact to the brain. We explored two potential therapeutic agents: the dietary supplement L-carnitine—a potential reserve source of ATP for the brain—and the cardiac drug mildronate, which inhibits L-carnitine but activates alternative compensatory pathways for the brain to adapt to metabolic disturbances. We found that L-carnitine injections could protect against mtDNA depletion by promoting mitochondrial biogenesis. However, they also appeared to aggravate inflammatory responses, likely due to changes in the composition of the gut microbiome. On the other hand, mildronate enhanced the expression of genes related to angiogenesis while also reducing local and systemic inflammation. Therefore, both compounds, despite their opposing metabolic effects, have the potential to be used in the treatment of secondary injuries caused by TBI.

21 January 2022 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
MIMikhail Ivanov
Mikhail Ivanov
NFNadezhda Konstantinovna Fursova
Nadezhda Konstantinovna Fursova
VPV. D. Potapov
V. D. Potapov
The significant increase in the number of antibiotic-resistant microorganisms observed in recent years is a public health problem worldwide. One of the molecular mechanisms for the formation of antimicrobial resistance in bacteria is the presence of efflux pumps. The review presents an analysis of experimental studies related to the study of efflux pumps in clinical strains of Pseudomonas aeruginosa, one of the representatives of hospital pathogens of the ESKAPE group. This review is intended for specialists developing new types of drugs against antibiotic-resistant strains, as well as researchers studying the mechanisms of bacterial resistance to antibiotics, heavy metals, biocides and other antimicrobial factors.

Verified
Journal Article
Open access
PDF file
VAViktoriya Vitalievna Antonova
Viktoriya Vitalievna Antonova
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Egor PlotnikovEgor Plotnikov
Egor Plotnikov
IPIrina B. Pevzner
Irina B. Pevzner
MIMikhail Ivanov
Mikhail Ivanov
AKArtem Kuzovlev
Artem Kuzovlev
The noble gas argon is one of the most promising neuroprotective agents for hypoxic-reperfusion injuries of the brain. However, its effect on traumatic injuries has been insufficiently studied. The aim of this study was to analyze the effect of the triple inhalation of the argon-oxygen mixture Ar 70%/O2 30% on physical and neurological recovery and the degree of brain damage after traumatic brain injury and to investigate the possible molecular mechanisms of the neuroprotective effect. The experiments were performed in male Wistar rats. A controlled brain injury model was used to investigate the effects of argon treatment and the underlying molecular mechanisms. The results of the study showed that animals with craniocerebral injuries that were treated with argon inhalation exhibited better physical recovery rates, better neurological status, and less brain damage. Argon treatment significantly reduced the expression of the proinflammatory markers TNFα and CD68 caused by TBI, increased the expression of phosphorylated protein kinase B (pAKT), and promoted the expression of the transcription factor Nrf2 in intact animals. Treatment with an argon-oxygen breathing mixture after traumatic brain injury has a neuroprotective effect by suppressing the inflammatory response and activating the antioxidant and anti-ischemic system.

15 September 2024 in RUDN Journal of Medicine
Verified
Journal Article
Open access
PDF file
ASAnastasia Sudina
Anastasia Sudina
MIMikhail Ivanov
Mikhail Ivanov
AYAlexander Yurin
Alexander Yurin
AMAndrey V. Makarov
Andrey V. Makarov
Timur FatkhudinovTimur Fatkhudinov
Timur Fatkhudinov
СИСалихова Д. И
Салихова Д. И
Relevance.The search for new methods of effective therapy for traumatic brain injury is one of the important tasks of modern biomedicine. One promising approach for treating traumatic brain injury is cell therapy. The aim of the work is to study the therapeutic effect of glial progenitor cells derived from induced pluripotent stromal cells in an experimental model of traumatic brain injury.Materials and Methods.Modeling of traumatic brain injury was carried out on mature male Wistar rats. The therapeutic group was administered asingle dose of 750*103cells/ml glial progenitor cells with avolume of 1 ml, and the control group — 1 ml of phosphate-­buffered saline. Administration was carried out intra-­arterially 24 hours after injury. To analyze the therapeutic effectiveness, an MRI study was performed on the 14th day, as well as alimb-placing test on the 1st, 3rd, 7th and 14th days. Histological examination was carried out on days 1, 3 and 7 after administration to assess the migration and distribution of stained cells (concentration 750*103cells/ml) by lipophilic dye PKH26 (Sigma, USA) at the rat’s brain tissues after traumatic brain injury. Measurements of injury volume and counts of PKH26-stained cells were performed using ImageJ software (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, USA). The statistical analysis was carried out using GraphPad Prism 8.2.0 program (GraphPad Software, Inc., USA).Results and Discussion.Administration of GPCs led to decreasing the damage volume. Significant decrease in sensorimotor deficit was observed on days 3, 7 and 14 after injury compared with the control group. Intra-arterial administration resulted in successful delivery of glial progenitor cells to brain tissue. Cells were detected in the cerebral cortex, hippocampus, and striatum on day 1, and were not observed on days 3 and 7 after administration.Conclusion.Intra-arterial administration of GPCs leads to efficient migration of cells into brain tissue. Glial progenitor cells therapy promotes neurorecovery processes after traumatic brain injury. This therapy is apromising treatment for traumatic brain injury.